DXCM Q2 CY2025 Deep Dive: Volume Growth, Leadership Changes, and New Product Launches Shape Outlook

Medical device company DexCom (NASDAQ:DXCM) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 15.2% year on year to $1.16 billion. The company expects the full year’s revenue to be around $4.61 billion, close to analysts’ estimates. Its non-GAAP profit of $0.48 per share was 7.8% above analysts’ consensus estimates.

Is now the time to buy DXCM? Find out in our full research report (it’s free).

StockStory’s Take

DexCom’s second quarter 2025 results saw the company surpass Wall Street’s revenue and earnings expectations, though the market’s immediate reaction was notably negative. Management attributed the quarter’s strong performance to sustained demand from both new and existing customers, with particular momentum among the type 2 non-insulin diabetes population. CEO Kevin Sayer emphasized DexCom’s expanding coverage through the three largest pharmacy benefit managers (PBMs), which now provides reimbursement for nearly 6 million type 2 non-insulin lives this year. The company also pointed to operational investments aimed at restoring inventory levels and supporting customer supply, as well as continued momentum in international markets, especially with DexCom ONE+. Collectively, these factors illustrate DexCom’s ability to drive growth through access expansion, operational execution, and product innovation.

Looking forward, DexCom’s updated guidance underscores management’s focus on broadening access for type 2 non-insulin users and driving global adoption of its continuous glucose monitoring (CGM) platform. The company is preparing for the commercial launch of its longer-wear 15-day G7 sensor and deepening software integration, including new AI-powered features and partnerships with digital health platforms. Incoming President Jake Leach stated that DexCom will continue to prioritize innovation, increased scale, and operational excellence. At the same time, CFO Jereme Sylvain noted that evolving reimbursement dynamics—including competitive bidding proposals for Medicare and international policy changes—could impact growth and margin trends in the coming years, requiring disciplined execution and adaptability.

Key Insights from Management’s Remarks

In their second quarter remarks, DexCom’s management attributed the company’s performance to broad-based demand, expanded insurance coverage, and the rapid rollout of new digital health features. The team also highlighted operational improvements, advances in product innovation, and a well-planned leadership transition. Their commentary throughout the call reflected a focus on building long-term relationships with prescribers, caregivers, and payers, as well as investing in technology and customer support. The management team described a multi-pronged strategy to sustain growth, improve patient outcomes, and scale DexCom’s global operations—even as they prepare for changes at the top of the organization.

• Type 2 market expansion: DexCom secured reimbursement with a third major PBM for type 2 non-insulin users, now providing coverage for nearly 6 million type 2 non-insulin lives in the U.S. This milestone helped drive significant growth in the segment and contributed to new customer adoption.
• Stelo traction builds: The over-the-counter Stelo glucose biosensor app surpassed 400,000 downloads, with its user base evolving from primarily type 2 non-insulin patients to increasingly wellness-focused and prediabetes segments as prescription CGM coverage broadened.
• International momentum: International revenue growth accelerated, fueled by expanded access for DexCom ONE+ and new public funding wins in major regions such as Ontario, Canada, and France. Management sees ongoing opportunities as more countries adopt broader access standards for CGM technology.
• Product innovation pipeline: DexCom emphasized a rapid cadence of development and deployment for new features, including AI-powered meal logging, direct-to-watch connectivity, and integration with third-party platforms like Oura. The company is preparing for the commercial introduction of its 15-day G7 sensor, which is anticipated to improve patient convenience and expand the addressable market.
• Leadership transition announced: CEO Kevin Sayer will hand over responsibilities to Jake Leach at the beginning of 2026; Leach stressed a commitment to continuity in DexCom’s strategic direction and a focus on global scaling and innovation.

Drivers of Future Performance

DexCom’s future performance will be shaped by the continued expansion of reimbursement, successful product launches, and ongoing investments in technology and market access. Management’s strategy is centered around increasing penetration among under-served populations, introducing new hardware and software capabilities, and maintaining operational resilience in the face of evolving competitive and regulatory headwinds. The company’s ability to deliver on these priorities will determine its growth trajectory and long-term market leadership.

• Broader access and uptake: Management underscored that increased PBM coverage and expanded international reimbursement are central to driving new patient adoption, particularly among type 2 non-insulin users. Penetrating under-served populations and building on recent access wins remain top priorities for the organization.
• Product releases and integration: The launch of the 15-day G7 sensor and continuous software enhancements—including AI-enabled features and new digital health partnerships—are expected to boost engagement, drive higher utilization rates, and strengthen retention. However, realizing these benefits will require seamless commercialization and effective payer negotiations.
• Potential headwinds: DexCom acknowledged early-stage uncertainty around proposed CMS competitive bidding for Medicare, which could impact pricing and margins as soon as 2027. The management team also noted that scaling operations and optimizing sales productivity is an ongoing process. Competitive activity, especially in the type 1 diabetes segment, will require the company to maintain its pace of innovation and differentiate through user experience and outcomes.

Catalysts in Upcoming Quarters

In the coming quarters, analysts will closely monitor (1) the commercial launch and adoption trajectory of the 15-day G7 sensor, (2) further expansion of PBM and international reimbursement for both prescription and over-the-counter CGM solutions, and (3) the impact of new software features and digital health integrations on patient engagement and utilization. Notably, leadership succession and any potential shifts in strategic priorities as Jake Leach prepares to assume the CEO role at the beginning of 2026 will also be under scrutiny. The ability to execute on these fronts will be critical to DexCom’s growth prospects and market positioning.

DexCom currently trades at $80.16, down from $89.11 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.

The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.